Risk factors and outcomes of Stenotrophomonas maltophilia Bacteraemia: A comparison with bacteraemia caused by Pseudomonas aeruginosaand acinetobacterspecies

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Hotta, Go ^a   Matsumura, Yasufumi ^a   Kato, Karin ^a   Nakano, Satoshi ^a   Yunoki, Tomoyuki ^a   Yamamoto, Masaki ^a   Nagao, Miki ^a   Ito, Yutaka ^a   Takakura, Shunji ^a   Ichiyama, Satoshi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; TIGECYCLINE;

ACINETOBACTER; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; INAPPROPRIATE PRESCRIBING; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; PROGNOSIS; PSEUDOMONAS AERUGINOSA; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; STENOTROPHOMONAS MALTOPHILIA; ACINETOBACTER INFECTIONS; COMPARATIVE STUDY; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDY; RISK FACTOR;

PSEUDOMONAS; STENOTROPHOMONAS MALTOPHILIA;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ADULT; AGED; BACTEREMIA; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MORTALITY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; STENOTROPHOMONAS MALTOPHILIA; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION;

EID: 84910649851     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112208     Document Type: Article

References (39)

1. Gales AC, Jones RN, Forward K.R., Liñares J, Sader H.S., et al. (2001) Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 32: S104-113.
2. Looney WJ, Narita M, Mühlemann K (2009) Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis 9: 312-323.
3. Fihman V, Le Monnier A, Corvec S, Jaureguy F., Tankovic J, et al. (2012) Stenotrophomonas maltophilia: The most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: A prospective multicenter study. J Infect 64: 391-398.
4. Brooke S (2012) Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 25: 2-41.
5. Senol E, DesJardin J, Stark P.C., Barefoot L., Snydman D.R. (2002) Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 34: 1653-1656.
6. Micozzi A, Venditti M, Monaco M., Friedrich A, Taglietti F, et al (2000) Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis 31: 705-711.
7. Metan G, Hayran M, Hascelik G., Uzun O. (2006) Which patient is a candidate for empiric therapy against Stenotrophomonas maltophilia bacteraemia? An analysis of associated risk factors in a tertiary care hospital. Scand J Infect Dis 38: 527-531.
8. Apisarnthanarak A, Mayfield JL, Garison T, McLendon P.M., DiPersio JF, et al. (2003) Risk factors for Stenotrohphomonas maltophilia bacteremia in oncology patients: A case-control study. Infect Control Hosp Epidermiol 24: 269-274.
9. Victor MA, Arpi M, Bruun B., Jønsson V, Hansen MM (1994) Xanthomonas maltophilia bacteraemia in immunocompromised haematological patients. Scand J Infect Dis 26: 163-170.
10. Charlson ME, Pompei P, Ales K.L., MacKenzie C.R. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40: 373-383.
11. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent J.L. (2001) Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286: 1754-1758.
12. Bone RC, Balk RA, Cerra F.B., Dellinger RP, Fein AM, et al. (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644-1655.
13. Clinical and Laboratory Standards Institute (2012) Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement M100-S22. CLSI, Wayne, PA, USA.
14. Cohen Stuart J., Mouton JW, Diederen B.M., Al Naiemi N, Thijsen S, et al (2010) Evaluation of Etest to determine tigecycline MICs for Enterobacter species. Antimicrob Agents Chemother 54: 2746-2747.
15. Muder RR, Harris AP, Muller S, Edmond M., Chow JW, et al. (1996) Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter Study of 91 episodes. Clin Infect Dis 22: 508-512.
16. Araoka H, Baba M, Yoneyama A. (2010) Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996-2009. Eur J Clin Microbiol Infect Dis 29: 605-608.
17. Friedman ND, Korman TM, Fairley C.K., Franklin JC, Spelman D.W. (2002) Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect 45: 47-53.
18. Hanes SD, Demirkan K, Tolley E., Boucher BA, Croce MA, et al. (2002) Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 35: 228-235.
19. Denton M, Todd NJ, Littlewood JM (1996) Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 15: 402-405.
20. Nseir S, Di Pompeo C, Brisson H, Dewavrin F., Tissier S, et al. (2006) Intensive care unit-aquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. Crit Care 10: R143.
21. Jang TN, Lee SH, Huang C.H., Lee CL, Chen C.Y. (2009) Risk factors and impact of nosocomial Acinetobacter baumanii bloodstream infections in the adult intensive care unit: a case-control study. J Hosp Infect 73: 143-150.
22. Trouillet JL, Chastre J, Vuagnat A., Jolly-Guillou ML, Combaux D, et al (1998) Ventilator-associated pneumonia caused by potencially drug-resistant bacteria. Am J Respir Crit Care Med 157: 531-539.
23. Marshall WF, Keating MR, Anhalt J.P., Steckelberg J.M. (1989) Xanthomonas maltophilia: an emerging nosocomial pathogen. Mayo Clin Proc 64: 1097-1104.
24. de Oliveira-Garcia D, Dall'Agnol M, Rosales M, Azzuz AC, Martinez MB, et al. (2002) Characterization of flagella produced by clinical strains of Stenotropho-monas maltophilia. Emerg Infect Dis 8: 918-923.
25. Vartivarian SE, Papadakis KA, Anaissie E.J. (1996) Stenotrophomonas (Xantho-monas) maltophilia urinary tract infection: a disease that is usually severe and complicated. Arch Intern Med 156: 433-435.
26. Samonis G, Karageorgopoulos DE, Makari S, Levis P., Dimopoulou D, et al. (2012) Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome. PLoS One 7: e37375.
27. Horcajada JP, Shaw E, Padilla B., Pintado V, Calbo E, et al (2012) Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance. Clin Microbiol Infect 19: 962-968.
28. Lai CH, Chi CY, Chen H.P., Chen TL, Lai CJ, et al. (2004) Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect 37: 350-358.
29. Boktour M, Hanna H, Ansari S., Bahna B, Hachem R, et al. (2006) Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients. Cancer 106: 1967-1973.
30. Paez JI, Costa S.F. (2008) Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect 70: 101-108.
31. Garazi M, Singer C, Tai J., Ginocchio C.C. (2012) Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review. J Hosp Infect 81: 114-118.
32. Tunger O, Vural S, Cetin C.B., Keles G., Gazi H. (2007) Clinical aspects and risk factors of nosocomial Stenotrophomonas maltophilia bacteremia episodes in a Turkish intensive care unit. J Chemother 19: 658-664.
33. Metan G, Uzun O. (2005) Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia. Antimicrob Agents Chemother 49: 3980-3981.
34. Wu H, Wang JT, Shiau Y.R., Wang HY, Lauderdale TL, et al. (2012) A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. J Microbiol Immuno Infect 45: 120-126.
35. Nicodemo AC, Paez J.I. (2007) Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 26: 229-237.
36. Wang YL, Scripione MR, Dubrovskava Y, Papadopoulos J. (2014) Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother 58: 176-82.
37. Cho SY, Kang CI, Kim J, Ha Y.E., Chung DR, et al.(2014) Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomo-nas maltophilia bacteremia? Antimicrob Agents Chemother 58: 581-3.
38. Wu ZB, Pan SM, Yu J, Liu Y., Yang XF, et al. (2011) Use of Diversilab repetitive sequence-based polymerase chain reaction system for genotyping Stenotropho-monas maltophilia isolates in different wards of one hospital. J Hosp Infect 79: 172-188.
39. Baba H, Nimmo GR, Allworth A.M., Boots RJ, Hayashi Y, et al. (2011) The role of surveillance cultures in the prediction of susceptibility patterns of gramnegative bacilli in the intensive care unit. Eur J Clin Microbiol Infect Dis 30: 739-44.